Effect of combination treatment of rapamycin and isoflavones on mtor pathway in human glioblastoma (U87) cells

Neurochemical Research

Volumn 35, Issue 7, 2010, Pages 986-993

  Puli, Shilpa ^a   Jain, Aditi ^a   Lai, James C K ^a   Bhushan, Alok ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Glioblastoma; Isoflavones; MTOR; Rapamycin

Indexed keywords

BIOCHANIN A; GENISTEIN; INITIATION FACTOR 4E; ISOFLAVONE DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; EUKARYOTIC INITIATION FACTOR-4E; GENISTEIN; GLIOBLASTOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOFLAVONES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77953230474     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-010-0142-2     Document Type: Article

References (66)

1. Central Brain Tumor Registry of the Unites States. Statistical report: primary brain tumors in the Unites States, 2000-2004. CBTRUS; 2007-2008
2. Kufe DW, Pollock RE, Weichselbaum RR et al (2004) Cancer Medicine 6. BC Decker, New York, pp 1195-1231
3. Jeffrey Bruce: Glioblastoma Multiforme. eMedicine February, (2005)
4. RM Baldwin DA Parolin IA Lorimer 2008 Regulation of glioblastoma cell invasion by PKC iota and RhoB Oncogene 27 25 3587 3595 10.1038/sj.onc.1211027 1:CAS:528:DC%2BD1cXmslWlsrg%3D 18212741 (Pubitemid 351793806)
5. IW Tremont-Lukats MR Gilbert 2003 Advances in molecular therapies in patients with brain tumors Cancer Control 10 2 125 137 12712007
6. AM Omuro S Faivre E Raymond 2007 Lessons learned in the development of targeted therapy for malignant gliomas Mol Cancer Ther 6 7 1909 1919 10.1158/1535-7163.MCT-07-0047 1:CAS:528:DC%2BD2sXnsVyqu7k%3D 17620423 (Pubitemid 47052481)
7. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer Nat Rev Cancer 2 489 501 10.1038/nrc839 1:CAS:528: DC%2BD38XkvFKltLs%3D 12094235
8. AJ Wong SH Bigner DD Bigner, et al. 1987 Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification Proc Natl Acad Sci 84 6899 6903 10.1073/pnas.84.19.6899 1:CAS:528:DyaL1cXktVyq 3477813
9. H Ohgaki 2005 Genetic pathways to glioblastomas Neuropathology 25 1 1 7 10.1111/j.1440-1789.2004.00600.x 15822813 (Pubitemid 40477707)
10. G Choe S Horvath TF Cloughesy, et al. 2003 Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo Cancer Res 63 2742 2746 1:CAS:528:DC%2BD3sXkt1aju7w%3D 12782577
11. A Chakravarti G Zhai Y Suzuki, et al. 2004 The prognostic significance of phosphotidylinositol 3-kinase pathway activation in human gliomas J Clin Oncol 22 10 1926 1933 10.1200/JCO.2004.07.193 1:CAS:528:DC%2BD2cXptlCksrY%3D 15143086 (Pubitemid 41095185)
12. Cheng JQ, Nicosia SV (2001) AKT signal transduction pathway in oncogenesis. Encylopedia reference of cancer. Springer, Berlin, pp 35-37
13. D Koul R Shen S Bergh, et al. 2006 Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma Mol Can Therap 5 3 637 644 10.1158/1535-7163.MCT-05-0453 1:CAS:528:DC%2BD28Xitl2ltLY%3D
14. N Hay N Sonenberg 2004 Upstream and downstream of mTOR Genes Dev 18 1926 1945 10.1101/gad.1212704 1:CAS:528:DC%2BD2cXmvFKqsLk%3D 15314020 (Pubitemid 39071573)
15. F Kaper N Dornhoefer AJ Giaccia 2006 Mutation in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions Cancer Res 66 3 1561 1569 10.1158/0008-5472.CAN-05-3375 1:CAS:528:DC%2BD28XpsVensw%3D%3D 16452213 (Pubitemid 43259938)
16. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target of cancer therapy Nat Rev Cancer 4 335 348 10.1038/nrc1362 1:CAS:528:DC%2BD2cXjsFSlu7Y%3D 15122205
17. M Hidalgo EK Rowinsky 2000 The rapamycin-sensitive signal transduction pathway as a target for cancer therapy Oncogene 19 6680 6686 10.1038/sj.onc.1204091 1:CAS:528:DC%2BD3MXhsF2rs7w%3D 11426655 (Pubitemid 32197708)
18. JP Dutcher 2004 Mammalian target of rapamycin inhibition Clin Cancer Res 10 6382 6387 10.1158/1078-0432.CCR-050008 (Pubitemid 39287496)
19. AC Gingras B Raught N Sonenberg 2001 Regulation of translation initiation by FRAP/mTOR Genes Dev 15 807 826 10.1101/gad.887201 1:CAS:528: DC%2BD3MXivVams7k%3D 11297505 (Pubitemid 32295062)
20. S Huang PJ Houghton 2002 Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic Curr Opinion Invest Drugs 3 295 304 1:CAS:528:DC%2BD38Xmt1WqsLs%3D
21. L Dudkin MB Dilling PJ Cheshire, et al. 2001 Biochemical correlates of mTOR inhibition by the rapamycin ester CC1-779 and tumor growth inhibition Clin Cancer Res 7 1758 1764 1:CAS:528:DC%2BD3MXltV2hsL4%3D 11410517
22. J Chen Y Fang 2004 A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling Biochem Pharmacol 64 1071 1077 10.1016/S0006-2952(02) 01263-7
23. LH Wei H Su IJ Hildebrandt, et al. 2008 Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma Clin Cancer Res 14 11 3416 3426 10.1158/1078-0432.CCR-07-1824 1:CAS:528:DC%2BD1cXmslygsbs%3D 18519772
24. DA Reardon A Desjardins JJ Vredenburgh, et al. 2010 Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma J Neurooncol 96 2 219 230 10.1007/s11060-009-9950-0 1:CAS:528:DC%2BC3cXpsVSjtA%3D%3D 19562254
25. K Yu L Toral-Barza C Discafani, et al. 2001 mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocr Relat Cancer 8 249 258 10.1677/erc.0.0080249 11566616 (Pubitemid 32947647)
26. N Gao Z Zhang BH Jiang, et al. 2003 Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer Biochem Biophys Res Commun 310 4 1124 1132 10.1016/j.bbrc.2003.09.132 1:CAS:528:DC%2BD3sXotVCisL4%3D 14559232 (Pubitemid 37237653)
27. E Galanis JC Buckner MJ Maurer, et al. 2005 Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 23 23 5294 5304 10.1200/JCO.2005.23. 622 1:CAS:528:DC%2BD2MXpslOrtLw%3D 15998902 (Pubitemid 46206983)
28. EM Duerr B Rollbrocker Y Hayashi, et al. 1998 PTEN mutations in gliomas and glioneuronal tumors Oncogene 16 17 2259 2264 10.1038/sj.onc.1201756 1:CAS:528:DyaK1cXjtFegtbw%3D 9619835
29. MS Neshat IK Mellinghoff C Tran, et al. 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR PNAS 98 18 10314 10319 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D 11504908 (Pubitemid 32803017)
30. S Huang PJ Houghton 2001 Resistance to rapamycin: a novel anticancer drug Cancer Metastasis Rev 20 1-2 69 78 10.1023/A:1013167315885 11831650 (Pubitemid 34074681)
31. S Huang PJ Houghton 2001 Mechanisms of resistance to rapamycins Drug Resist Updat 4 6 378 391 10.1054/drup.2002.0227 1:CAS:528:DC%2BD38Xlsl2hsbc%3D 12030785 (Pubitemid 34746872)
32. TF Cloughesy K Yoshimoto P Nghiemphu, et al. 2008 Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 5 1 e8 10.1371/journal.pmed.0050008 18215105 (Pubitemid 351198268)
33. RD Rao AC Mladek JD Lamont, et al. 2005 Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells Neoplasia 7 10 921 929 10.1593/neo.05361 1:CAS:528:DC%2BD2MXhtlClurvP 16242075
34. RK Goudar Q Shi MD Hjelmeland, et al. 2005 Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition Mol Cancer Ther 4 1 101 112 1:CAS:528:DC%2BD2MXksFyqsA%3D%3D 15657358
35. L Doherty DC Gigas S Kesari, et al. 2006 Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas Neurology 67 1 156 158 10.1212/01.wnl.0000223844.77636.29 1:CAS:528:DC%2BD28XlvFylu7c%3D 16832099 (Pubitemid 44305484)
36. TN Kreisl AB Lassman PS Mischel, et al. 2009 A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) J Neurooncol 92 1 99 105 10.1007/s11060-008-9741-z 1:CAS:528:DC%2BD1MXhtVGjtLY%3D 19018475
37. S Paternot PP Roger 2009 Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation Cancer Res 69 11 4577 4581 10.1158/0008-5472.CAN-08-3260 1:CAS:528:DC%2BD1MXmsFGltLY%3D 19458076
38. LJ Costa RM Gemmill HA Drabkin 2007 Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells Urology 69 3 596 602 10.1016/j.urology.2007.01.053 17382186 (Pubitemid 46428416)
39. V Persky L Van Horn 1995 Epidemiology of soy and cancer: perspectives and directions J Nutr 125 3 709S 712S 1:CAS:528:DyaK2MXktFGlsrw%3D 7884555
40. S Barnes TG Peterson 1995 Biochemical targets of the isoflavone genistein in tumor cell lines Proc Soc Exp Biol Med 208 1 103 108 1:CAS:528: DyaK2MXivFehtLY%3D 7892283
41. T Fotsis M Pepper H Adlercreutz, et al. 1993 Genistein, a dietary-derived inhibitor of in vitro angiogenesis Proc Natl Acad Sci USA 90 7 2690 2694 10.1073/pnas.90.7.2690 1:CAS:528:DyaK3sXit1Ggsrw%3D 7681986
42. T Akiyama J Ishida S Nakagawa, et al. 1987 Genistein, a specific inhibitor of tyrosine-specific protein kinases J Biol Chem 262 12 5592 5595 1:CAS:528:DyaL2sXktF2rurk%3D 3106339
43. YS Lee JS Seo HT Chung, et al. 1991 Inhibitory effects of biochanin A on mouse lung tumor induced by benzo(a)pyrene J Korean Med Sci 6 4 325 328 1:CAS:528:DyaK3sXks1amtLg%3D 1844641
44. J Hempstock JP Kavanagh NJ George 1998 Growth inhibition of prostate cell lines in vitro by phyto-oestrogens Br J Urol 82 4 560 563 1:CAS:528: DyaK1cXnsVWrurw%3D 9806188
45. L Rice VG Samedi TA Medrano, et al. 2002 Mechanisms of the growth inhibitory effects of the isoflavonoid biochanin A on LNCaP cells and xenografts Prostate 52 3 201 212 10.1002/pros.10100 1:CAS:528:DC%2BD38XmsVWqtbo%3D 12111696 (Pubitemid 34791222)
46. PL Penar S Khoshyomn A Bhushan, et al. 1997 Inhibition of epidermal growth factor receptor-associated tyrosine kinase blocks glioblastoma invasion of the brain Neurosurgery 40 1 141 151 10.1097/00006123-199701000-00032 1:STN:280:DyaK2s7is12lug%3D%3D 8971836 (Pubitemid 26425661)
47. PL Penar S Khoshyomn A Bhushan, et al. 1998 Inhibition of glioma invasion of fetal brain aggregates In Vivo 12 1 75 84 1:CAS:528:DyaK1cXis1Kktbs%3D 9575429
48. Sehdev V, Lai JC, Bhushan A (2009) Biochanin A modulates cell viability, invasion and growth promoting signaling pathways in HER-2-positive breast cancer cells. J Oncol (In Press)
49. S Puli A Bhushan JC Lai 2006 Inhibition of matrix degrading enzymes and invasion in human glioblastoma (U87MG) cells by isoflavones J Neurooncol 79 2 135 142 10.1007/s11060-006-9126-0 1:CAS:528:DC%2BD28XhtFemtLvL 16598420 (Pubitemid 44349940)
50. SY Sun LM Rosenberg X Wang, et al. 2005 Activation of Akt and eIF4E survival pathways by rapamycin mediated mammalian target of rapamycin inhibition Cancer Res 65 16 7052 7058 10.1158/0008-5472.CAN-05-0917 1:CAS:528: DC%2BD2MXns1Wrt7c%3D 16103051 (Pubitemid 41161231)
51. X Hu PP Pandolfi Y Li, et al. 2005 mTOR promotes survival and astrocytic characteristics induced by Pten/Akt signaling in glioblastoma Neoplasia 7 4 356 368 10.1593/neo.04595 1:CAS:528:DC%2BD2MXkvFeqtLs%3D 15967113 (Pubitemid 40664225)
52. MB Dilling P Dias DN Shapiro, et al. 1994 Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor Cancer Res 54 4 903 907 1:CAS:528:DyaK2cXitVyju74%3D 7508822
53. H Hosoi MB Dilling LN Liu, et al. 1998 Studies on the mechanism of resistance to rapamycin in human cancer cells Mol Pharmacol 54 815 824 1:CAS:528:DyaK1cXntlOntLg%3D 9804616
54. JS Eshleman BL Carlson AC Mladek, et al. 2002 Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy Cancer Res 62 7291 7297 1:CAS:528:DC%2BD3sXhtV2jsA%3D%3D 12499272
55. AB Heimberger E Wang EC McGary, et al. 2005 Mechanism of action of rapamycin in gliomas Neuro Oncol 7 1 1 11 10.1215/S1152851704000420 1:CAS:528:DC%2BD2MXhvFyrsbg%3D 15701277 (Pubitemid 40310188)
56. T Haruta T Uno J Kawahara, et al. 2000 A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1 Mol Endocrinol 14 6 783 789 10.1210/me.14.6.783 1:CAS:528:DC%2BD3cXlt1Wgtr8%3D 10847581 (Pubitemid 32260492)
57. DH Kim DD Sarbassov SM Ali, et al. 2002 mTOR interacts with raptor to form nutrient-sensitive complex that signals to the cell growth machinery Cell 110 163 175 10.1016/S0092-8674(02)00808-5 1:CAS:528:DC%2BD38XlvV2htr4%3D 12150925 (Pubitemid 34876545)
58. N Oshiro K Yoshino S Hidayat, et al. 2004 Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function Genes Cells 9 359 366 10.1111/j.1356-9597.2004.00727.x 1:CAS:528:DC%2BD2cXjsVGqu7o%3D 15066126 (Pubitemid 38514871)
59. DD Sarbassov DA Guertin SM Ali, et al. 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 5712 1098 1101 10.1126/science.1106148 1:CAS:528:DC%2BD2MXhtlSrtbY%3D 15718470 (Pubitemid 40262113)
60. RJ Dowling M Pollak N Sonenberg 2009 Current status and challenges associated with targeting mTOR for cancer therapy Bio Drugs 23 2 77 91 1:CAS:528:DC%2BD1MXovFSnsbo%3D
61. N Gulati M Karsy L Albert, et al. 2009 Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility Int J Oncol 35 4 731 740 1:CAS:528:DC%2BD1MXht1Wju7nP 19724909
62. A Toschi E Lee L Xu, et al. 2009 Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin Mol Cell Biol 29 6 1411 1420 10.1128/MCB.00782-08 1:CAS:528:DC%2BD1MXjt1Wls7o%3D 19114562
63. J Masri A Bernath J Martin, et al. 2007 mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor Cancer Res 67 24 11712 11720 10.1158/0008-5472.CAN-07-2223 1:CAS:528: DC%2BD2sXhsVCjs7vJ 18089801
64. J Werzowa D Cejka T Fuereder, et al. 2009 Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002 Br J Dermatol 160 5 955 964 10.1111/j.1365-2133.2008. 08991.x 1:CAS:528:DC%2BD1MXlvFOisrg%3D 19120326
65. DA Reardon JA Quinn JJ Vredenburgh, et al. 2006 Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma Clin Can Res 12 3 860 868 10.1158/1078-0432.CCR-05-2215 1:CAS:528:DC%2BD28XhtFeiu74%3D (Pubitemid 43259869)
66. HG Wendel E De Stanchina JS Fridman, et al. 2004 Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy Nature 428 6980 267 269 10.1038/nature02369 (Pubitemid 38418805)